DocGo Third Quarter Earnings Call - DOCGO INC

Explicit Guidance:

• FY2026 Revenue: Revised guidance lowered to approximately $300 million (previously $305–$310 million); excludes Acuity Health transaction revenue expected to close late 2026/early 2027.
• FY2026 Adjusted EBITDA: Reaffirmed loss guidance of $17–$22 million.
• Q4 2026 Implied Revenue: Management projects implied Q4 revenue in the $77–$78 million range to achieve the full-year target.
• FY2027 Outlook (No Formal Guidance): Explicitly states no formal 2027 guidance issued due to CEO transition; however, management anticipates positive EBITDA for the full year 2027 with high single-digit revenue growth in medical transportation and growth across all mobile health segments.
• Profitability Run Rate: Expectation to exit 2026 at a profitable run rate.

Business-Segment Outlook:

• Care-in-the-Home: Transitioning from loss to positive adjusted EBITDA on a contribution basis by late 2026 or very early 2027; expects substantial revenue growth in 2027 following Q3 volume reductions (down 26%) and model restructuring (mixing LPNs with phlebotomists/medical assistants).
• Medical Transportation: Excluding the upstate NY wind-down, segment gross margin is projected to approach 37%. Growth expected to be driven by NYC, Delaware, Wisconsin, and Tennessee markets; focus shifting in 2027 from pure volume gains to portfolio management (payor mix, service levels like BLS vs. ALS) to maximize average price per trip.
• Mobile Health: Non-migrant revenue increased 64% YoY in Q3. SteadyMD margins normalized in September and are expected to improve further in Q4 due to seasonality.
• Upstate NY Wind-down: Expected to contribute an approximate $3 million adjusted EBITDA loss reduction in 2027 (vs. 2026 loss); revenue impact is being phased out gradually through FY2026 rather than a single-quarter drop.
• Revenue Mix Breakdown (FY2026): Medical Transportation ($205–$210M); SteadyMD ($30–$35M); Clinical Staffing ($14–$15M); Remote Patient Monitoring ($16–$17M); Mobile Phlebotomy ($5–$6M); Care-in-the-Home ($7–$9M).

Market and Competitive Outlook:

• Demand Trends: Increasing demand observed across most markets; Q4 expected to be seasonal peak for SteadyMD and Care-in-the-Home.
• Pricing and Margins: Gross margin improvement driven by pricing optimization and exit of sub-par contracts; management notes that "fundamentally flawed" markets (e.g., CA, CO) have been exited, while "tricky" markets (e.g., PA, NJ) can be profitable with proper reimbursement.
• Structural Changes: Shift from emergency-response focus to vertically integrated hybrid care (virtual + in-person); deliberate reduction in unprofitable contract volume to prioritize margin over top-line growth in FY2026.
• CMS Regulatory: New CMS requirements for RPM (requiring a physician well-visit for enrollment) viewed as a positive tailwind for DocGo's integrated service model.

Macro / Industry Outlook:

• Fuel Costs: Elevated fuel prices (avg $4.18/gallon in Q3) currently depressing margins by ~52 bps in transport; expected to provide a tailwind if prices moderate in 2027.
• FX: No specific FX commentary provided.
• Regulation: CMS fee schedule updates viewed as aligned with company capabilities.

Strategic Initiatives:

• M&A (Acuity Health): Closing expected late November/early December 2026; includes $12 million debt facility tranche contingent on closing; $25 million additional tranche available if mobile health revenue exceeds $130 million (current run rate >$150 million).
• M&A (SteadyMD): Acquisition from Oct 2025 integrated; full-year contribution included in FY2026; future incremental revenue from 2027 growth.
• Pennsylvania Expansion: Launching care-in-the-home program in PA leveraging existing medical transportation infrastructure and unit-economic models.
• AI Implementation: Deployment of automated AI voice agents for outreach reduced cost per booking by >50%; scaling back manual outreach in Q3 to deploy these efficiencies.
• Workforce: Significant corporate headcount reductions in June and September; continued focus on operational efficiency to target SG&A of $28 million per quarter for break-even.
• Receivables Collection: Progress on $19 million in discontinued municipal receivables; smaller portion ($6.7M) to be collected imminently; larger portion ($12.6M) resolved late 2026/early 2027.

Risks and Headwinds to Outlook:

• Fuel Price Volatility: Continued elevated fuel costs could restrain margin expansion.
• Contract Renegotiation Success: Two-thirds of the $60M "negative margin" portfolio requires successful restructuring/negotiation to become EBITDA-positive in 2027.
• Receivable Timing: Resolution of $12.6M receivable could slip into early 2027.
• Seasonality & Volume: Potential seasonality in Q4 (SteadyMD/Care-in-the-Home) requires careful volume management; risk of under-delivering on seasonal ramp if volume targets are missed.
• CEO Transition: Leadership transition could impact execution timing; new CEO search requires specific restructuring/turnaround skills.

Management Tone on the Future:

• Confidence: Optimistic and proud; expresses strong conviction in the company's ability to create value as healthcare evolves.
• Priorities: Explicit shift from "revenue at all costs" to "profitability and cash flow."
• Caveats: Management emphasizes that 2027 positive EBITDA is a projection, not a guarantee, contingent on sustainable margins and receivable collections.

Miscellaneous:

• CEO Transition: CEO Lee Beanstalk remaining until at least March 31, 2027.
• Liquidity: Unrestricted cash of $19.1 million at 9/30/26; debt facility provides flexibility to minimize borrowings as profitability advances.
• Cash Flow: Operating cash burn improving (down to $3–$4M in Q3 from $18M YTD); positive operating cash flow anticipated 1–2 quarters after hitting EBITDA break-even (potentially Q1/Q2 2027).